We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amneal Pharmaceuticals (AMRX - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Amneal Pharmaceuticals is a member of the Medical sector. This group includes 932 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 5.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, AMRX has gained about 8.8% so far this year. Meanwhile, stocks in the Medical group have gained about 7.6% on average. As we can see, Amneal Pharmaceuticals is performing better than its sector in the calendar year.
Biohaven Ltd. (BHVN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 14%.
The consensus estimate for Biohaven Ltd.'s current year EPS has increased 47.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 141 individual stocks and currently sits at #95 in the Zacks Industry Rank. This group has gained an average of 2.3% so far this year, so AMRX is performing better in this area.
On the other hand, Biohaven Ltd. belongs to the Medical - Biomedical and Genetics industry. This 453-stock industry is currently ranked #88. The industry has moved +19.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Amneal Pharmaceuticals and Biohaven Ltd. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amneal Pharmaceuticals (AMRX - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Amneal Pharmaceuticals is a member of the Medical sector. This group includes 932 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 5.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, AMRX has gained about 8.8% so far this year. Meanwhile, stocks in the Medical group have gained about 7.6% on average. As we can see, Amneal Pharmaceuticals is performing better than its sector in the calendar year.
Biohaven Ltd. (BHVN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 14%.
The consensus estimate for Biohaven Ltd.'s current year EPS has increased 47.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 141 individual stocks and currently sits at #95 in the Zacks Industry Rank. This group has gained an average of 2.3% so far this year, so AMRX is performing better in this area.
On the other hand, Biohaven Ltd. belongs to the Medical - Biomedical and Genetics industry. This 453-stock industry is currently ranked #88. The industry has moved +19.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Amneal Pharmaceuticals and Biohaven Ltd. as they could maintain their solid performance.